Pharmacoeconomic analyses are performed preferentially in developed countries where there is an imperative to obtain "value for money" and to achieve cost-effectiveness. Such analyses are performed in low-income/ developing countries and middle-income countries, partly to save scarce resources but also to improve the overall economic outlook, promote productivity gains, and foster further investment in vaccination. Analyses appear to be performed preferentially for therapeutic products as opposed to vaccines, but this may change as the impact of applying the results of pharmacoeconomic analyses of vaccines are measured and quantified. (J Pediatr Inf 2014; 8: 110-20) 
Introduction
Are pharmacoeconomic analyses performed preferentially in developed countries? If they are, is this because there is a greater desire to obtain "value for money" in developed countries as opposed to developing countries? Should it not be the other way around? Are such analyses performed preferentially for therapeutic products as opposed to vaccines? Are the results of such analyses more impactful in developed or in developing countries? These and other questions will be addressed by this review of published studies performed over the last 2 decades.
As implied above, the impact of favorable (or unfavorable) pharmacoeconomic analyses can be enormous, in that they are used to guide decision-making. Perhaps the most striking example of this impact (in developed countries) is that of the UK National Institute for Health and Care Excellence (NICE), where guidance is based on measures, such as quality-adjusted life-years, where randomized controlled clinical trials are used as the benchmark if possible and where modeling is performed and thresholds are set.
Similar health technology assessment exercises are performed in many other developed countries, such as the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, the Canadian Agency for Drugs and Technologies in Health (CADTH), the Scottish Medicines Consortium (SMC), and the Zorg Instituut Nederland (Care Institute NL). In fact, the European Medicines Agency works closely with the European Network for Health Technology Assessment (EUnetHTA), although pharmacoeconomic analyses are still generally a national issue. Despite the relative sophistication of the drug reimbursement decision-making processes in countries of the Organisation for Economic Co-operation and Development (OECD), one health policy analysis reported that only 5 of 33 OECD countries (Ireland, Norway, Portugal, Slovak Republic, and Slovenia) had fully transparent systems, using both clinical and costeffectiveness evidence, and have a formal appeal mechanism to a separate committee from that that made the first decision (1) . Notably, it is the latter that is lacking in countries, such as England, Scotland, and the Netherlands.
Responding to the perceived need for health technology assessment exercises to be performed in developing countries, the Health Technology Assessment International Interest Sub-Group on Developing Countries (HTAi DC ISG) was launched in 2008. Furthermore, it is being recognized that health technology assessments will play an increasing role in the future development of the healthcare sector in countries, such as India (2) , and international organizations, such as the Pan American Health Organization, have been instrumental in defining health technology assessment methodologies suitable for developing countries (3). We caution, however, that published state-of-the-art health economic research can be misleading. Correspondence regarding how health economic research is represented from South Africa (4) draws attention to the shortcomings of what is purported to be a systematic review of health economic research in South Africa (5) .
The purpose of this review is to compare and contrast pharmacoeconomic analyses in developing and developed countries.
Material and Methods
Medline searches were performed, covering the period from 1996 to June 2014, using the terms "pharmacoeconomics" or "pharmaceutical economics" and "vaccines" or "immunization" (search A), and for the period from 2013 to June 2014 using the terms "cost-benefit analysis" or "cost-effectiveness" and "vaccines" or "immunization" (search B). A third search was performed to help answer the question about pharmacoeconomic analyses in therapeutics as opposed to vaccines, for the period from 2013 to June 2014 simply using the term "pharmacoeconomics" (search C). No language or country restrictions were imposed. No unpublished studies were sought. Papers were considered relevant if there was an attempt to quantify cost-benefit, cost-utility, cost-effectiveness or cost-minimization and/or if there was an attempt to gather data for such purposes.
Results
Search (A) yielded 40 citations, of which 27 were relevant (Table 1) . Search (B) yielded 150 citations, of which 86 were relevant ( Table 2 ). Only one citation (6) was common to both searches.
There were 20 studies (17% of a total of 112) devoted to developing (low-income) countries (see Tables 1  and 2 for references). Five deal directly with African countries: a malaria vaccine for sub-Saharan Africa, a rotavirus vaccine for Ethiopia (grouped with India), a rotavirus vaccine for Malawi, a pneumococcal conjugate vaccine for Kenya, and a measles vaccine for South Africa. Four deal with India: one study addressing all vaccines, one addressing rotavirus (the one grouped with Ethiopia), and two addressing Hib. While Brazil and Mexico are otherwise grouped with "middle-income countries," other Latin America countries are represented by 9 studies: pneumococcal conjugate vaccine (6), human papilloma virus (HPV), rotavirus vaccine [2 grouped with pneumococcal vaccine (PCV)], the expanded program on immunization (EPI) (1), Hib (1 grouped with PCV and rotavirus), and varicella. Three remaining studies cover HPV in all developing countries (7), vaccines for neglected diseases in Advance Market Commitment countries (8) , and the measles/rubella vaccine as part of the Global Vaccine Action Plan (9) .
Regarding middle-income countries, there were 14 studies (Tables 1, 2) <: PCV in Turkey, Mexico, and Thailand; 2 studies on Hib; 3 studies on HPV (including 1 in Malaysia); 1 study on meningococcal conjugate vaccine in Brazil; 1 on rotavirus vaccine in Indonesia; 2 studies on dengue vaccine in Brazil; and 1 study each on hepatitis A virus vaccine and influenza vaccine.
There were 13 studies that took a "global" perspective (Tables 1, 2) : not surprisingly, influenza vaccination was represented by 4 studies; varicella and HPV were represented by 2 each; rotavirus vaccine, poliomyelitis vaccine, and rubella vaccine were represented by 1 each; and 2 studies addressed "all" vaccines (10, 11) .
The remaining 75 studies were thus directed towards analyses performed in developed countries (Tables 1, 2 ). These consisted of: 10 each for pneumococcal conjugate vaccine and human papillomavirus vaccine; 9 each for rotavirus vaccine and influenza vaccine; 7 for pertussis or Tdap; 5 for varicella vaccine; 4 each for meningococcal vaccine and HBV vaccine; 3 each for MMR and "all" vaccines; and 1 each for respiratory syncytial virus (RSV) vaccine, "varicella/pneumococcal/pertussis/HAV in the elderly," and for vaccine barcodes" (the total adds up to more than 75, because several studies covered more than 1 vaccine).
Search (C) produced 125 studies (in any country) of relevance: 3 relating to vaccines, 83 relating to specific therapeutic areas, and 39 relating to "generic" aspects of pharmacoeconomic analyses (Table 3) .
Discussion
The main observation is that a wide variety and breadth of vaccines have been studied in all age groups and in many countries. There are relatively few analyses (17%) directly related to developing countries. The possible reasons may be the lack of reliable input data (12) or the lack of resources to provide the vaccine, even if it was shown to be cost-effective (13) . Even so, when pharmacoeconomic studies are performed, as for example in a study of medications at two tertiary care hospitals in Pakistan, one of the stated reasons for performing the study was "to save economic resources" (14) . However, in a study on the prevention of cervical cancer in the Brazilian Amazon region, which, for the purposes of this paper, was classified as "developing," the authors conclude that HPV vaccination "has a favorable profile in terms of cost-utility, and its inclusion in the immunization schedule would result in a substantial reduction in incidence and mortality" (15) . This is similar to the conclusion drawn in a study of the introduction of pneumococcal conjugate vaccine in Kenya, which would be "highly cost-effective from a societal perspective" (16) , and of Hib conjugate vaccine in India, which would also be cost-effective (17) .
One novel solution is proposed in the application of cost-effectiveness analyses in developing countries, using the example of rotavirus vaccination in India and Ethiopia (18) . The authors propose that incorporating financial risk protection and distributional consequences across the whole wealth strata of the country into the economic evaluation of vaccine policy enables "selection of vaccine packages based on the quantitative inclusion of information on equity and on how much financial risk protection is being bought per dollar expenditure on vaccine policy, in addition to how much health is being bought." Another rotavirus example, this time from Malawi, noted that the cost of implementation would be high when compared with the government health budget per capita and that new financing opportunities were necessary (19) . A study on the cost of the Colombian Expanded Program on Immunization proposes using standardized tools to improve cost data for program planning (20) . A number of studies have been performed in the following middle-income countries: Turkey, Mexico, Thailand, Malaysia, Brazil, and Indonesia. By contrast with the stated reasons for performing such studies in developing countries, it is more likely that the reasons for performing them in middle-income countries are to improve the overall economic outlook, promote productivity gains, and foster further investment in vaccination (21) . A review of economic evaluations of hepatitis A virus vaccination in middle-income countries suggests that such vaccination could be cost-saving (22), while a Turkish study, highly populated with local data, suggests that pneumococcal conjugate vaccination in Turkey would be very cost-effective as an intervention (6) . Another review of the economic evaluation of influenza vaccination in middle-income countries came to the conclusion that in middle-income countries, "influenza vaccination provided value for money for elderly, infants, adults, and children with high-risk conditions" (23) . However, the authors went on to note that "serious methodological limitations do not allow drawing conclusions on cost-effectiveness of influenza vaccination in middleincome countries" and that "evidence on cost-effectiveness from low-income countries is lacking altogether."
We caution, however, that the published state-of-theart health economic research can be misleading. In correspondence regarding how health economic research is represented from South Africa, the authors Gow et al. (4) draw attention to the shortcomings of what is purported to be a systematic review of health economic research in South Africa (5) .
The analyses performed in developed countries are most likely performed to minimize costs to the healthcare system in exchange for the maximum benefit and/or define a level of cost-effectiveness. An in-depth examination of economic evaluations of vaccines in Europe was performed by Postma et al. (11) , citing the need for models to be, at times, rather complex.
Regarding the imbalance in published studies-there being more studies addressing therapeutic areas rather than vaccines-this is partly due to the larger number of therapeutic medicines as opposed to prophylactic vaccines and partly due to the sometimes very expensive costs of some therapeutics. But, it is the imbalance within "therapeutic" studies that is also notable-there being a predominance of studies in oncology, immunology, and rheumatology. Again, this is likely to be due to the sometimes very expensive costs in these therapeutic areas and the need to provide justification for using healthcare resources in these areas. There are some attempts to look into the future-prophylaxis of HPV to prevent future cervical cancer in lowand middle-income countries (13, 24), severity-based analyses for influenza pandemics (25) , prophylaxis of HBV to prevent future hepatocellular carcinoma (22, 26, 27) and there are also attempts to look at vaccines under development: malaria (28), dengue (29, 30), and RSV (31) . There are also a few studies looking at the potential for the "elimination" of measles (9, (32) (33) (34) .
What is clear is that pharmacoeconomic analyses have been performed and continue to be performed when new vaccines appear, when "old" vaccines are studied in new situations, and when economic predictions need to be made to direct resource allocation. While there is a relative paucity of analyses in lowincome/developing countries and a relative paucity of data to be inserted into the models, those analyses performed in these situations are helpful in guiding policy decisions. One hesitates to recommend standardization because of the great heterogeneity between low-income/ developing countries themselves and between them and middle-income and developed countries. Nevertheless, a degree of cross-country and cross-regional cooperation would be helpful.
Conclusion
Pharmacoeconomic analyses are performed preferentially in developed countries, where there is an imperative to obtain "value for money" and to achieve costeffectiveness. Such analyses are performed in lowincome/developing countries and middle-income countries partly to save scarce resources but also to improve the overall economic outlook, promote productivity gains, and foster further investment in vaccination. Analyses appear to be performed preferentially for therapeutic products as opposed to vaccines, but this may change, as the impact of applying the results of pharmacoeconomic analyses of vaccines are measured and quantified.
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